News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
The protease-activated Cas9 enzymes could reduce off-target effects and could be used to sense pathogens and trigger an immune response.
GreenLight Biosciences is using a proprietary cell-free RNA production technology to develop RNA-based products for the agricultural market.
The partners will work to find novel proteins, including DNA endonucleases, to develop new gene editing therapies for cystic fibrosis and other diseases.
Ohio State University researchers found that a phosphorothioate-modified DNA-crRNA duplex completely blocked the function of Cas12a.
The firm is developing and beta-testing a line of guide RNA libraries to support CRISPR-based targeted capture and sequencing approaches.
Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.
Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.
A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.
In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.
This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.